Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance | Zendy

Annamaria Colao | Zendy; Rosario Pivonello | Zendy; Renata S. Auriemma | Zendy; Maria Cristina De Martino | Zendy; Martin Bidlingmaier | Zendy; Francesco Briganti | Zendy; Fabio Tortora | Zendy; Pia Burman | Zendy; IONE A. KOURIDES | Zendy; Christian J. Strasburger | Zendy; Gaetano Lombardi | Zendy

Open Access

Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance

Author(s) -

Annamaria Colao,

Rosario Pivonello,

Renata S. Auriemma,

Maria Cristina De Martino,

Martin Bidlingmaier,

Francesco Briganti,

Fabio Tortora,

Pia Burman,

IONE A. KOURIDES,

Christian J. Strasburger,

Gaetano Lombardi

Publication year - 2006

Publication title -

european journal of endocrinology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.897

H-Index - 148

eISSN - 1479-683X

pISSN - 0804-4643

DOI - 10.1530/eje.1.02112

Subject(s) - pegvisomant , acromegaly , medicine , endocrinology , octreotide , lanreotide , somatostatin , blood pressure , basal (medicine) , antagonist , gastroenterology , hormone , receptor , diabetes mellitus , growth hormone

We aimed to investigate the efficacy of pegvisomant in patients with acromegaly resistant to long-term (> or = 24-month), high-dose treatment with octreotide-LAR (40 mg/month) or lanreotide (120 mg/month).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research